ClearTrial Named a "Cool Vendor in Life Sciences, 2011" by GartnerGartner

ClearTrial Named a "Cool Vendor in Life Sciences, 2011" by GartnerGartner defines a Cool Vendor as a company that offers technologies or solutions that are innovative, impactful and intriguing.  Click on the button at right to view and download the full report.

ClearTrial is in the list of "Cool Vendors" in the "Cool Vendors in Life Sciences, 2011" report by Gartner, Inc.  Authored by Gartner Research Vice President Steven Lefebure and Gartner Managing Vice President Dale Hagemeyer, the report explores key challenges faced by life sciences companies and discusses the ClearTrial solution for planning, forecasting, and tracking of clinical project and financial performance.

Published on April 22, 2011, the Gartner "Cool Vendors in Life Sciences, 2011" report identifies technology companies in the life sciences that are:

Innovative, enable users to do things they couldn't do before
Impactful, have, or will have, business impact (not just technology for the sake of technology)
Intriguing, have caught Gartner's interest or curiosity in approximately the past six months
According to the report, "Life science companies collect vast amounts of structured and unstructured data from clinical and commercial efforts. However, classic business intelligence tools are often inadequate to handle this data in a way that provides value for the enterprise."

About the Gartner Cool Vendor Selection Process:
Gartner is a registered trademark of Gartner, Inc. or its affiliates. The Gartner listing does not constitute an exhaustive list of vendors in any given technology area, but rather is designed to identify interesting, new and innovative vendors, products and services. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Each year, Gartner identifies a Cool Vendor as a company that offers technologies or solutions that are: innovative-enabling users to do things they couldn't do before; impactful-have, or will have, business impact (not just technology for the sake of technology); and intriguing-have caught our interest or curiosity in approximately the past six months.

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.